1) Thiele EA, Marsh ED, French JA, et al. Cannabidiol (CBD) Significantly Reduces Drop Seizure Frequency in Lennox-Gastaut Syndrome (LGS): Results of a Multi-center, Randomized, Double-blind, Placebo-controlled Trial (GWPCARE4). Lancet 2017; 376;2011-20. 2) Autry AR, Trevathan E, Van Naarden Braun K, Yeargin-Allsopp M. Increased risk of death among children with Lennox-Gastaut syndrome and infantile spasms. J Child Neurol. 2010;25(4):441-447. 3) LGS Foundation. About Lennox-Gastaut Syndrome. Disponible el http://www.lgsfoundation.org/aboutlgs. C... 23 de octubre de 2017. 4) National Institute of Health. Lennox-Gastaut syndrome. Disponible en https://ghr.nlm.nih.gov/condition/lennox-gastaut-syndrome#de... ado el 23 de octubre de 2017.
Consultas: GW Pharmaceuticals plc Stephen Schultz, vicepresidente de relaciones para inversores (EE. UU.) +1-917-280-2424 / +1-401-500-6570 Consultas para medios de EE. UU.: Sam Brown Inc. Healthcare Communications Christy Curran +1-615-414-8668 Mike Beyer, +1-312-961-2502 Consultas para medios de la UE: FTI Consulting Con Franklin, +44(0)7817-573-659
